Dimensional Fund Advisors LP decreased its position in shares of Stryker Corporation (NYSE:SYK – Free Report) by 1.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,242,500 shares of the medical technology company’s stock after selling 18,151 shares during the period. Dimensional Fund Advisors LP owned 0.32% of Stryker worth $408,258,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Godfrey Financial Associates Inc. purchased a new position in Stryker in the fourth quarter worth $26,000. Sankala Group LLC purchased a new position in shares of Stryker during the 4th quarter worth about $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the 3rd quarter worth $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker during the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG acquired a new position in shares of Stryker during the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.
Insider Buying and Selling at Stryker In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by insiders.
Analysts Set New Price Targets Several research analysts recently commented on SYK shares. JPMorgan Chase & Co. cut their price target on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Canaccord Genuity Group decreased their price target on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Evercore set a $350.00 target price on Stryker in a report on Monday, July 6th. Citigroup reduced their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Finally, Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $392.52.
Read Our Latest Stock Analysis on Stryker
Stryker Price Performance Shares of NYSE:SYK opened at $313.89 on Wednesday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company has a market cap of $120.33 billion, a price-to-earnings ratio of 36.33, a PEG ratio of 2.04 and a beta of 0.77. The business has a 50 day moving average price of $313.79 and a 200 day moving average price of $336.20. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87.
Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts predict that Stryker Corporation will post 14.99 earnings per share for the current year.
Stryker Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.
Stryker Company Profile (Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Further Reading Five stocks we like better than Stryker Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEToll Brothers Inc. $TOL Shares Bought by Dimensional Fund Advisors LP
NEXT HEADLINE »California Public Employees Retirement System Boosts Stake in Nordson Corporation $NDSN
Assetmark Inc. boosted its position in shares of Stryker Corporation (NYSE:SYK – Free Report) by 791.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,693 shares of the medical technology company’s stock after acquiring an additional 31,687 shares during the period. Assetmark Inc.’s holdings in Stryker were worth $11,728,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of SYK. Brighton Jones LLC increased its holdings in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. purchased a new position in Stryker in the 2nd quarter worth approximately $205,000. Marshall Wace LLP raised its position in shares of Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after buying an additional 77,831 shares in the last quarter. Nebula Research & Development LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at $219,000. Finally, HUB Investment Partners LLC bought a new stake in shares of Stryker during the 2nd quarter worth $253,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity In other news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 323,264 shares of company stock valued at $100,659,489. Insiders own 4.60% of the company’s stock.
Analysts Set New Price Targets SYK has been the subject of several research reports. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Truist Financial reiterated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Canaccord Genuity Group reduced their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research report on Friday, May 1st. Finally, Needham & Company LLC decreased their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $392.52.
Read Our Latest Stock Report on SYK
Stryker Stock Performance NYSE:SYK opened at $318.80 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The firm has a market cap of $122.22 billion, a PE ratio of 36.90, a price-to-earnings-growth ratio of 2.05 and a beta of 0.77. The business has a 50 day moving average price of $313.41 and a 200-day moving average price of $336.46.
Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the previous year, the firm earned $2.84 earnings per share. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts predict that Stryker Corporation will post 14.99 earnings per share for the current year.
Stryker Announces Dividend The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is presently 40.74%.
Stryker Company Profile (Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Read More Five stocks we like better than Stryker The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEIQVIA Holdings Inc. $IQV Shares Bought by Andra AP fonden
NEXT HEADLINE »Assetmark Inc. Grows Stake in Alibaba Group Holding Limited $BABA
Andra AP fonden lifted its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 30.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 65,055 shares of the medical technology company’s stock after acquiring an additional 15,095 shares during the quarter. Andra AP fonden’s holdings in Stryker were worth $21,376,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Long Road Investment Counsel LLC raised its position in shares of Stryker by 0.9% during the 1st quarter. Long Road Investment Counsel LLC now owns 42,957 shares of the medical technology company’s stock valued at $14,115,000 after purchasing an additional 401 shares during the period. Johnson Financial Group Inc. lifted its stake in shares of Stryker by 123.9% during the 1st quarter. Johnson Financial Group Inc. now owns 2,803 shares of the medical technology company’s stock valued at $924,000 after buying an additional 1,551 shares in the last quarter. AlTi Global Inc. boosted its holdings in Stryker by 124.9% in the 1st quarter. AlTi Global Inc. now owns 2,085 shares of the medical technology company’s stock worth $687,000 after buying an additional 1,158 shares during the period. Earned Wealth Advisors LLC boosted its holdings in Stryker by 12.1% in the 1st quarter. Earned Wealth Advisors LLC now owns 2,766 shares of the medical technology company’s stock worth $909,000 after buying an additional 299 shares during the period. Finally, Hollencrest Capital Management increased its stake in Stryker by 0.7% in the 1st quarter. Hollencrest Capital Management now owns 25,438 shares of the medical technology company’s stock worth $8,359,000 after buying an additional 180 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In Several equities analysts have recently commented on the company. Argus set a $370.00 price objective on Stryker in a research report on Thursday, July 9th. Barclays cut their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. Wells Fargo & Company decreased their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Leerink Partners lowered their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Finally, Citigroup dropped their price target on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $392.52.
Read Our Latest Report on Stryker
Stryker Stock Performance Shares of NYSE SYK opened at $318.80 on Tuesday. The company has a market cap of $122.22 billion, a P/E ratio of 36.90, a P/E/G ratio of 2.05 and a beta of 0.77. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The firm’s fifty day moving average is $313.41 and its two-hundred day moving average is $336.46.
Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts anticipate that Stryker Corporation will post 14.99 EPS for the current fiscal year.
Stryker Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is presently 40.74%.
Insider Activity at Stryker In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 323,264 shares of company stock valued at $100,659,489. Insiders own 4.60% of the company’s stock.
Stryker Profile (Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Articles Five stocks we like better than Stryker The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAssetmark Inc. Raises Stock Holdings in Bio-Rad Laboratories, Inc. $BIO
NEXT HEADLINE »Assetmark Inc. Raises Holdings in ITT Inc. $ITT
Key Takeaways Stryker launched Mako RPS, a handheld robotic platform for total knee replacement procedures.Mako RPS pairs robotic technology with the Triathlon Total Knee System and familiar workflows.The platform uses real-time active adjustment and integrates with the Q Guidance System. Stryker (SYK - Free Report) recently announced the U.S. commercial launch of Mako RPS (Robotic Power System), a handheld robotic platform developed for total knee replacement procedures. The system introduces Mako Handheld Robotics, extending the Mako robotics portfolio into a new segment of the orthopedic robotics market.
According to Lisa Kloes, vice president and general manager of Stryker’s Knee business, Mako RPS integrates robotic technology with the clinically proven Triathlon Total Knee System to provide surgeons with an intuitive surgical experience while preserving the familiarity of the implant and workflow they already use and trust.
Per Keith Evans, vice president and general manager of Stryker’s Mako and Enabling Technologies business, customer response during the limited market release has been exceptionally strong. Mako RPS sets a new benchmark for handheld robotic technology by combining robotic capabilities, power tool expertise and a deep understanding of surgical workflows.
Likely Trend of SYK Stock Following the NewsFollowing the announcement, SYK shares gained 4.7% at yesterday’s close. Year to date, shares of the company have fallen 5.8% compared with the industry’s 20% decline. However, the S&P 500 has risen 10% in the same timeframe.
Stryker is likely to benefit from the commercial launch of Mako RPS, as the new platform broadens its orthopedic robotics portfolio and strengthens its leadership in robotic-assisted joint replacement. The launch could support higher adoption among surgeons while expanding the company’s reach to customers and care settings that may not have adopted robotic-assisted surgery. Compatibility with Stryker’s widely used Triathlon Total Knee System and Q Guidance System may further reinforce its integrated orthopedic ecosystem and create long-term growth opportunities.
SYK currently has a market capitalization of $121.31 billion.
Image Source: Zacks Investment Research
More on Mako RPSThe Mako RPS marks the introduction of Stryker's Mako Handheld Robotics platform while complementing the company's Mako SmartRobotics with Mako 4 multi-specialty robotic-arm-assisted platform. Mako RPS offers surgeons an intuitive handheld robotic experience that combines Stryker's expertise in robotics and power tools, broadening access to robotic-assisted orthopedic procedures.
Compatible with Stryker's clinically proven Triathlon Total Knee System, Mako RPS features intraoperative planning and a robotically enabled saw equipped with the company's patented active adjustment technology. The system responds to the surgeon's hand movements to maintain alignment with the surgical plan in real time. It eliminates the need for cutting blocks, enabling surgeons to adopt robotic technology without changing their existing workflows.
Built to integrate with Stryker’s multi-specialty Q Guidance System, Mako RPS expands the company’s ecosystem of enabling technologies across orthopedic care. The launch also builds on the strong global presence of the Mako platform, which has supported more than 2.5 million procedures across 47 countries over the past two decades, highlighting Stryker’s continued focus on advancing robotic innovation in orthopedics.
Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the orthopedic devices market is valued at $68.64 billion in 2026 and is expected to witness a CAGR of 4.3% through 2035.
The market is expanding, driven by the rising prevalence of orthopedic disorders, an aging population and injury incidence, integration of robotics and artificial intelligence in orthopedic surgeries and greater healthcare access and reimbursement support.
Other NewsStryker recently announced the launch of TPX HD, an advanced small bone power tool engineered to support performance, control and ergonomics across a range of complex orthopedic procedures. The tool is intended for use in total joint revisions, minimally invasive surgery and oral maxillofacial procedures.
SYK’s Zacks Rank & Key PicksStryker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
New handheld robotic technology expands the Mako platform and brings Mako robotic-assisted knee replacement to a new segment of the orthopaedic market
Stryker announced the U.S. commercial launch of Mako RPS (Robotic Power System) for total knee replacement procedures. The launch introduces Mako Handheld Robotics, expanding the Mako portfolio beyond robotic-arm assisted surgery. Mako RPS combines robotic execution, intraoperative planning and a familiar handheld power tool workflow. , /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today the U.S. commercial launch of Mako RPS® (Robotic Power System) for total knee replacement procedures, further expanding the Mako portfolio into a new category of orthopaedic robotics.
Mako RPS® (Robotic Power System)
Mako RPS® (Robotic Power System) The launch marks the introduction of the Mako Handheld Robotics platform, alongside the Mako SmartRobotics™ with Mako 4, Stryker's multi-specialty robotic-arm assisted platform. Designed to provide surgeons with an intuitive handheld robotic experience, Mako RPS combines Stryker's expertise in robotics and power tools to bring robotic technology to a new customer segment of the orthopaedic market.
"Customer response during the limited market release has been exceptionally strong," said Keith Evans, VP/GM of Stryker's Mako and Enabling Technologies business. "As we expand the Mako portfolio, we're proud to set a new standard for what customers can expect from a handheld robotics technology – bringing together robotics, power tool expertise and a deep understanding of surgical workflows."
As healthcare providers increasingly seek flexibility in how robotic technology is incorporated into orthopaedic procedures, Mako RPS offers a new option that blends robotic execution with a familiar surgical experience. The launch expands access to Mako, offering surgeons more robotic options and bringing Mako to a broader range of customers and care settings.
Compatible with Stryker's clinically proven1-2 Triathlon® Total Knee System, Mako RPS for Total Knee features intraoperative planning and a robotically enabled saw equipped with Stryker's patented active adjustment technology, which responds to a surgeon's hand movements and helps maintain alignment with the surgical plan in real time. The system provides a familiar cutting experience without the need for cutting blocks, offering an option for surgeons interested in adopting robotic technology while integrating easily into their existing surgical workflows.
"By combining robotic technology with the clinically proven Triathlon® Total Knee System, Mako RPS delivers an intuitive surgical experience that builds on the implant and workflow familiarity surgeons know and trust2-3," said Lisa Kloes, vice president and general manager of Stryker's Knee business.
Built to work with Stryker's multi-specialty Q Guidance System, Mako RPS expands Stryker's ecosystem of enabling technologies across the continuum of orthopaedic care and sites of service.
For more than two decades, Mako has defined orthopaedic robotics worldwide. With more than 2.5 million procedures performed in 47 countries, Mako continues to advance the adoption of robotics in orthopaedics and support surgeons in delivering personalized patient care.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
American Joint Replacement Registry (AJRR): 2025 Annual Report. Rosemont, IL: American Academy of Orthopaedic Surgeons (AAOS), 2025. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty Annual Report 2025. AOA;2025. https://aoanjrr.sahmri.com/. Accessed 11 Oct. 2025 Scott CEH, Snowden GT, Cawley W, et al. Fifteen-year prospective longitudinal cohort study of outcomes following single radius total knee arthroplasty. Bone Jt Open. 2023;4(10):808-816. Published 2023 Oct 24.doi:10.1302/2633-1462.410.BJO-2023-0086.R1 SOURCE Stryker
SummaryStryker remains a high-quality MedTech compounder despite a rare Q1 miss driven by a temporary cyber disruption.Q1 weakness was not demand-driven; full-year guidance is unchanged and end-market demand remains healthy.Current valuation reflects temporary disruption, offering a more attractive entry into SYK, though the stock is not cheap.I rate SYK as 'Buy' due to its resilient business model, strong execution history, and improved entry point. JHVEPhoto/iStock Editorial via Getty Images
Stryker (SYK) is rarely cheap, and usually for good reason. This is one of the best execution stories in MedTech: strong products, consistent innovation, a leading orthopedic robotics platform, and a long track record of growth.
99 Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of SYK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Stryker Corporation offers a compelling medtech investment, benefiting from robust industry growth and an innovation-led strategy. SYK trades at a 13% discount to fair value, with a forward P/E of 20.1 versus a 10-year average of 25.6. Consensus expects SYK's adjusted diluted EPS to compound at 11.2% annually through 2028, supporting high single-digit dividend growth.
Stryker is a Dividend Aristocrat with 32 years of increases, robust cash flow, and a strong M&A-driven growth strategy. SYK's Q1 2026 results were impacted by a cybersecurity incident, but management maintained full-year guidance and expects normalization. The stock trades at ~21x 2026E EPS, below its 5-year average, suggesting undervaluation despite recent share price declines.
Stryker (NYSE:SYK | SYK Price Prediction) and Intuitive Surgical (NASDAQ:ISRG) both closed the books on Q1 2026 with sharply different results. Stryker absorbed a March 11 cyberattack and heavy restructuring charges while defending its joint replacement franchise. Intuitive posted another crisp beat on the back of da Vinci 5 adoption. Two medtech giants, two very different quarters.
A Cyber Hit for Stryker, A Clean Beat for Intuitive Stryker reported $6.02 billion in revenue, missing the $6.33 billion consensus, with adjusted EPS of $2.60 falling short of the $2.98 estimate. Yet Knees grew 4.7%, Hips rose 3.7%, and Trauma and Extremities expanded 9.5%. The Mako-driven ortho story is intact. Vascular, powered by the Inari deal, jumped 27.5%. CEO Kevin Lobo said the team could “recover quickly from the cyber incident” and kept full-year guidance of 8.0% to 9.5% organic growth.
Intuitive delivered $2.77 billion in revenue, up 23.0%, with non-GAAP EPS of $2.50 topping the $2.11 consensus. Worldwide da Vinci procedures rose roughly 16%, and 232 of the 431 systems placed were the new da Vinci 5. Instruments and Accessories, the recurring flywheel, climbed 23% to $1.69 billion.
An Orthopedic Compounder vs. A Soft Tissue Pure Play Stryker sells to almost every corner of the operating room. Intuitive depends almost entirely on robotic soft tissue procedures. That framing shapes how each business absorbs shocks.
Lens Stryker Intuitive Surgical Core Bet Mako-led joint replacement plus diversified medsurg da Vinci 5 rollout and Ion lung platform Recurring Engine Ortho consumables, trauma, vascular Instruments and accessories tied to procedure volume Key Vulnerability Cyber and restructuring charges of $118 million Tariff hit of roughly 1.0% of revenue and hospital capex risk Valuation Forward P/E near 22 Forward P/E near 39 The demographically driven wave of joint replacements keeps Stryker’s ortho volumes remarkably sticky, and Lobo hit a $25 billion revenue milestone in 2025. Intuitive, meanwhile, guided da Vinci procedure growth of 13.5% to 15.5%, a step down from 18% in 2025. Growth is still enviable, though the deceleration is real.
The Next Test Is Guidance Credibility Stryker’s stock is down 19.6% over the past year at $314.84, so investors clearly want proof the cyber hit was one time. I want Q2 organic growth to snap back toward the high single digits. Intuitive has slid 26.82% to $397.68, and the question is whether da Vinci 5 placements can offset a softer procedure ramp and tariff drag.
Why I Lean Toward Stryker on This Quarter Given the setup, I lean toward Stryker for durable exposure. The Mako franchise, the Inari-boosted vascular arm, and free cash flow that jumped 226.77% to $415 million even during a messy quarter look like the profile of a structural compounder. For investors comfortable with a richer multiple, Intuitive’s procedure flywheel remains intact. I would only revisit that view if hospital capex tightens further or tariffs escalate.
Want Up To $1,000? SoFi Is Giving New Active Invest Users Free StockLooking to grow your money but unsure where to begin? SoFi Active Invest is offering a limited-time promotion—open an account, fund it with $50 or more, and you could receive up to $1,000 in complimentary stock for Active Invest accounts.
From $0 commission trading to fractional shares and automated investing, this app is designed to simplify investing for everyone, whether you’re just starting or already experienced. Its easy to sign up and secure your bonus.
July 01, 2026 08:00 ET | Source: Stryker Corporation
Portage, Michigan, July 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) will host a webcast at 4:30 p.m. (Eastern time) on Thursday, July 30, 2026, to discuss its second quarter 2026 financial results. The live webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available at Stryker’s website beginning approximately two hours after the live call ends.
An accompanying press release that includes summary financial information for the second quarter will be issued at approximately 4:05 p.m. (Eastern time) and available at Stryker - Press Releases on the day of the webcast.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected]
For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]
On June 30, 2026, Stryker Corp (SYK) shares fell 4.7% to a current price of $314.84. This decline comes in a challenging year where the stock has seen a year-to
Stryker (SYK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
, /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, today announced a new partnership with Major Champion and globally recognized golfer Shane Lowry at the Travelers Championship in Cromwell, Connecticut, naming him a sponsored brand ambassador for its Joint Replacement division. Through this collaboration, Lowry will share a deeply personal story, highlighting the critical role caregivers play in supporting loved ones through joint pain, surgery and recovery.
As a caregiver to his father, Brendan, a former Gaelic football player and knee and hip replacement recipient, Lowry brings a unique perspective, having seen firsthand the impact joint pain has on both patients and their families. Research shows that support from family and caregivers can positively impact recovery and outcomes.1,2 Together with Stryker, Lowry will help raise awareness of the experience someone struggling with joint pain may go through and empower caregivers to take an active role throughout their loved one's journey, from education to recovery.
"Watching my dad in pain because of his hip and knee was as hard as anything I've come across on the course. As a caregiver, you want to help, but it's not always clear where to start," said Lowry. "I've learned that asking the right questions, finding the right doctor and simply being there along the way can make a big difference. I didn't realize at the time how many Stryker technologies are out there to support those who suffer from joint pain, and I'm proud to now be partnering with a company helping people to keep moving forward. I hope sharing my story encourages others to take that first step with a loved one."
Through a global campaign spanning media, social channels and educational initiatives, Lowry will help elevate the role of caregivers and encourage a more proactive engagement in the joint replacement journey. By focusing on awareness, education and access to information, the campaign aims to support caregivers as they help loved ones take the first step, from understanding treatment options to navigating recovery.
"We know joint replacement is more than surgery – it's a personal journey that affects both patients and the people who support them every step of the way," said Katherine Truppi, president of Stryker's Joint Replacement division. "As we continue to move lives, we also value the essential and often underrecognized role caregivers play in helping loved ones navigate treatment decisions and recovery. Shane's story brings that perspective to life in an authentic and meaningful way that we hope can help more people."
Throughout the Travelers Championship, fans are invited to stop by the Fan Zone to learn about treatment options for joint pain.
For more information and downloadable resources, please visit www.MoveLivesTogether.com.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Wylde V, Kunutsor SK, Lenguerrand E, Jackson J, Blom AW, Beswick AD. Is social support associated with patient-reported outcomes after joint replacement? A systematic review and meta-analysis. Lancet Rheumatol. 2019;1(3):e174-e186. doi:10.1016/S2665-9913(19)30050-5 Singh J, Saag K, Lemay C, Allison J, Franklin P. Effect of Family Support on Short-and Intermediate Term Pain and Function Outcomes after Knee or Hip Replacement. Abstract Number 64 American College of Rheumatology Annual Meeting 2014. November 14-19, 2014. Boston, MA. SOURCE Stryker
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC - Free Report) and Stryker (SYK - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Phibro Animal Health has a Zacks Rank of #2 (Buy), while Stryker has a Zacks Rank of #3 (Hold) right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that PAHC has an improving earnings outlook. But this is just one piece of the puzzle for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
PAHC currently has a forward P/E ratio of 10.36, while SYK has a forward P/E of 20.54. We also note that PAHC has a PEG ratio of 0.48. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. SYK currently has a PEG ratio of 1.97.
Another notable valuation metric for PAHC is its P/B ratio of 3.57. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, SYK has a P/B of 5.14.
These are just a few of the metrics contributing to PAHC's Value grade of A and SYK's Value grade of D.
PAHC is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that PAHC is likely the superior value option right now.
Stryker Corp (SYK) Q1 2026 Earnings Call Highlights: Navigating Cyber Challenges and Strategic Growth Stryker Corp (SYK) maintains full-year guidance amidst cyber disruptions, with strong international sales and strategic acquisitions fueling optimism. Summary
Organic Sales Growth: 2.4% worldwide, 1.9% in the US, 3.9% internationally.Adjusted Earnings Per Share (EPS): $2.60, down 8.5% from the previous year.Adjusted Gross Margin: 63.6%, a decrease of 190 basis points from the previous year.Adjusted Operating Margin: 21.1% of sales, 180 basis points lower than the previous year.Adjusted Effective Tax Rate: 14.5% for the quarter.Cash from Operations: $581 million year-to-date.Full Year 2026 Guidance: Organic net sales growth expected to be 8% to 9.5%; adjusted net earnings per share expected to be $14.90 to $15.10.
Release Date: April 30, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points Stryker Corp SYK maintained its full-year guidance despite the cyber incident, indicating confidence in its recovery and market position.The company reported a record Q1 for Mako installations both in the US and internationally, with high utilization rates.Stryker Corp (SYK) announced the acquisition of Amplitude Vascular Systems, which is expected to expand its presence in the cardiovascular space.The launch of the new Ortho Tech business aims to simplify customer experience and accelerate innovation in the orthopedic segment.International sales growth was strong, with a 3.9% increase, driven by solid fundamentals and market positioning. Negative Points A cyber incident caused significant disruption to Stryker Corp (SYK)'s operations, impacting sales and manufacturing absorption.Adjusted earnings per share decreased by 8.5% from the previous year, primarily due to the cyber incident and increased interest expenses.The company's adjusted gross margin fell by 190 basis points compared to the first quarter of 2025, reflecting lost manufacturing absorption and tariffs.The Middle East conflict had a modest effect on international growth, although the overall impact was limited.The cyber incident led to delays in revenue recognition and shipment disruptions, affecting the timing of sales recovery throughout the year. Q & A Highlights Q: Can you provide more specific color on how we should think about the recovery in sales given the disruption from the cyber incident?
A: Preston Wells, CFO: The recovery will vary across our business due to different operating models. For example, in Orthopedics, revenue recognition items will be caught up in the second half of the year. Some procedures that were deferred will be rescheduled throughout the year. For MedSurg, which includes capital equipment, production delays will push recovery into the second half of the year. We expect some recovery in Q2, with more significant recovery in Q3 and Q4.
Q: How are you mitigating higher input costs due to inflation and geopolitical events?
A: Preston Wells, CFO: We expect some pressure from higher input costs, but our procurement team is actively working to mitigate these where possible. We have contracts in place to help manage these costs, and this is factored into our guidance. We anticipate being able to absorb these rising costs based on current conditions.
Q: What are you seeing competitively in the orthopedic market, especially with other companies reorganizing?
A: Kevin Lobo, CEO: We are confident in our position as market leaders in robotics, with strong uptake for Mako 4 and positive feedback on Mako Shoulder. We expect to continue outgrowing the orthopedic market by 200 to 300 basis points. Our full-year guidance reflects this confidence, and we anticipate acceleration towards the end of the year with new product launches.
Q: Can you discuss the impact of the cyber incident on different business segments, specifically MedSurg versus Orthopedics?
A: Preston Wells, CFO: In Orthopedics, many products are consigned at hospitals, allowing procedures to continue with revenue recognition deferred to Q2. MedSurg, which includes capital equipment, faced more significant production delays, pushing recovery into the second half of the year. We expect MedSurg recovery primarily in Q3 and Q4.
Q: How are you thinking about M&A as a contributor to top-line growth, given recent acquisitions like Amplitude Vascular Systems?
A: Kevin Lobo, CEO: We are excited about our deal pipeline and cash position, which allows us to pursue more acquisitions. We expect to be active in M&A through the end of this year and into next year, with a focus on expanding in areas like Peripheral Vascular and potentially other cardiovascular spaces.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
May 01, 2026 08:00 ET | Source: Stryker Corporation
Portage, Michigan, May 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13, 2026, at the Encore at Wynn Hotel in Las Vegas, Nevada.
Representing the company will be Spencer Stiles, President and Chief Operating Officer, Jason Beach, Vice President, Group Chief Financial Officer, MedSurg and Neurotechnology and Nick Mead, Vice President, Investor Relations. Their presentation is scheduled for 1:40 p.m. Pacific Time.
A live webcast and replay of the presentation will be accessible on Stryker’s website at www.stryker.com, and it will be archived on the Investor Relations page.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected]
For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]
Key Takeaways SYK reported Q1 EPS of $2.60, missing estimates by 12.8% and declining 8.5% year over year.Revenues rose 2.6% to $6.02B but missed estimates, hurt by cyber-driven production disruptions. Margins contracted due to shutdown impacts and tariffs, though MedSurg and Orthopedics saw growth. Stryker Corporation (SYK - Free Report) reported first-quarter 2026 adjusted earnings per share (EPS) of $2.60, which missed the Zacks Consensus Estimate of $2.98 by 12.8%. The bottom line declined 8.5% year over year.
GAAP EPS was $1.93, up 14.2% from the year-ago quarter’s level.
Revenue DetailsRevenues totaled $6.02 billion, which missed the Zacks Consensus Estimate by 4.4%. The top line improved 2.6% on a year-over-year basis and 1% at constant currency (cc).
Organically, sales were up 2.4%. Organic sales growth was driven by a 2.1% increase in unit volume and 0.3% improvement in prices.
Revenues by GeographyRevenues in the United States amounted to $4.48 billion, up 0.8% from the prior-year quarter’s level. International sales increased 8.3% year over year reportedly and 1.5% at cc to $1.54 billion.
Segmental AnalysisStryker divested its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space in April 2025. The company now posts its Spine enabling technologies results as part of other orthopedics. Interventional Spine results are reported as part of neurocrine. As a result, spinal implants are now reported separately within orthopedics.
Effective first-quarter 2026, Stryker realigned its reporting structure by combining the orthopaedic instruments portfolio from its Instruments business with the Mako and enabling technologies portfolio from Other Orthopaedics into a newly formed Ortho Tech segment.
MedSurg and Neurotechnology: This segment reported sales of $3.21 billion, up 5% year over year and 3.6% at cc.
In the quarter under review, MedSurg and Neurotechnology recorded organic sales growth of 0.9%. Instruments recorded U.S. sales growth of 19.1%.
Endoscopy saw a 1.2% U.S. decline. Medical declined 6.9% in the United States.
Vascular grew 37.9% in the United States.
Internationally, sales were up 11.7%, driven by growth across Endoscopy, Instruments, Medical and Vascular businesses.
Orthopedics: Sales in the segment amounted to $2.8 billion, up 0.1% year over year but down 1.8% at cc. Organically, sales were up 4.1%. The U.S. knee business grew 1.4%.
U.S. hips business grew 2.3%. Trauma and Extremities business improved 7.6% in the United States. U.S. Ortho Tech business grew 2%. International Orthopaedics grew 12.2%.
MarginsAdjusted gross profit totaled $3.83 billion in the reported quarter, down 0.5% from the year-ago quarter’s level. Adjusted gross margin contracted 190 basis points (bps) to 63.6%, reflecting the impact of lost manufacturing absorption from production shutdowns due to the cyber incident as well as the impact of tariffs.
Total operating expenses were $2.82 billion, down 21.4% from the year-ago quarter’s level.
Adjusted operating income totaled $1.27 billion, down 5.4% from the year-ago level. Adjusted operating margin was 21.1%, down 180 bps.
Financial UpdateStryker exited the first quarter with cash and cash equivalents of $2.97 billion compared with $4.01 billion at the end of the fourth quarter of 2025.
Cumulative net cash provided by operating activities totaled $581 million compared with $250 million a year ago.
2026 GuidanceStryker has maintained its guidance for 2026. The company expects total revenues to grow in the range of 8-9.5% on an organic basis. The Zacks Consensus Estimate for total revenues is pegged at $27.21 billion, implying growth of 8.3%.
SYK expects full-year 2026 EPS to be in the range of $14.90-$15.10. The Zacks Consensus Estimate for earnings is pegged at $14.91 per share.
Wrapping UpStryker exited the first quarter of 2026 with weaker-than-expected sales and earnings. The underperformance was primarily due to a late-quarter cyber incident that disrupted operations, delayed shipments and deferred revenue recognition. Despite these headwinds, underlying demand remained healthy across geographies, supported by solid procedural volumes and strong capital order trends. Margin pressure reflected lost manufacturing absorption, tariffs and higher interest expense tied to prior acquisitions.
SYK’s shares have lost 10.3% year to date compared with the industry’s 21.5% decline. The S&P 500 has increased 6.2% in the same time frame.
Image Source: Zacks Investment Research
Looking ahead, management expects recovery through 2026 as deferred procedures, production backlogs and revenue recognition normalize, particularly in the second half. Growth drivers include continued momentum in robotic surgery (Mako), new product launches and sustained hospital capital spending. Strategic acquisitions — especially Inari and the planned Amplitude Vascular Systems deal — highlight Stryker’s push into faster-growing cardiovascular markets, enhancing diversification beyond orthopaedics.
However, risks remain, including execution on recovery, tariff pressures, geopolitical uncertainties and integration complexity from expanding into new adjacencies. Still, diversified end markets and active M&A position Stryker for stronger growth in the back half of 2026.
Zacks Rank & Stocks to ConsiderStryker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) . While Globus Medical sports a Zacks Rank #1 (Strong Buy) at present, Phibro Animal Health and Cardinal Health carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical’s shares have gained 3.3% in the year-to-date period. Estimates for the company’s first-quarter 2026 EPS have increased 1 cent to 90 cents in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 18.79%. In the last reported quarter, it posted an earnings surprise of 20.75%.
Estimates for Phibro Animal Health’s third-quarter fiscal 2026 EPS have remained constant at 72 cents in the past 30 days. Shares of the company have risen 42.4% in the year-to-date period against the industry’s 20.5% decline. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.15%. In the last reported quarter, it delivered an earnings surprise of 26.09%.
Cardinal Health’s shares have declined 6.2% in the year-to-date period. Estimates for the company’s third-quarter 2026 EPS have decreased 1 cent to $2.80 in the past 30 days. CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 9.30%. In the last reported quarter, it posted an earnings surprise of 10.04%.
Stryker Corporation (NYSE:SYK) shares are trading sideways on Monday. But that wasn't the case on Friday. They dropped almost 6.5% after the company reported its earnings.
But the selloff may be over. There may even be a reversal. This is why Stryker is the Stock of the Day.
Many trading strategies and models are based on the concept of reversion to the mean. If a stock or security gets overextended in one direction, traders will be anticipating a reversal or reversion.
If a stock is oversold, like Stryker is, traders will come into the market as buyers because they will be expecting a move higher. Their buying could force the shares up.
The red line on the chart is two standard deviations below the 20-day moving average. According to statistics and probability theory, 95% of trading should occur within two standard deviations of the mean.
If a stock exceeds this threshold to the down-side like Stryker has, it is considered to be oversold. This will draw buyers into the market.
The shares are also at a price level that may provide support.
As you can see, this price was a resistance level in 2023. And sometimes, a price that had been a resistance level can turn into a support level.
There are investors and traders who sold at this level who were glad they did when the price dropped after.
But when this resistance was broken, a number of these investors and traders changed their minds. They decided that selling was a mistake.
Some of them also decided that if they could ever do so, they would buy their shares back at the same price they were sold for. Now that the share has finally dropped back to this level, they will place buy orders.
If there is a large quantity of these orders, it will create support at the level.
This combination of being oversold while at support can be a bullish dynamic. Stryker may be about to rally.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
May 07, 2026 08:00 ET | Source: Stryker Corporation
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the close of business on June 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected]
For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]
May 07, 2026 16:05 ET | Source: Stryker Corporation
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease.
“This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease,” said Kevin Lobo, Chair and CEO, Stryker. “By integrating AVS’s innovative CO₂-generated pressure wave technology with Stryker’s scale and resources, we are well-positioned to deliver solutions that support physicians and patient outcomes.”
The addition of an IVL platform will strengthen Stryker’s impact in peripheral vascular solutions.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
About Amplitude Vascular Systems (AVS)
Amplitude Vascular Systems (AVS) is a medical device company based in Boston, Mass., focused on treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital, Cue Growth Partners, and others. It was founded in 2017 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at the University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. More information is available at www.avspulse.com.
Contacts
For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected]
For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]
On May 12, 2026, we present a DCF analysis for Stryker Corp SYK , a company that has faced notable price performance challenges recently, with a year-to-date decline of 18.6% and a one-year drop of 24.6%. Below are key insights from our analysis:
DCF Earnings-based intrinsic value of $206.09 compared to current price of $282.58 (margin of safety: -37.1%) DCF FCF-based intrinsic value of $286.38 provides a second opinion on valuation (1.3% margin of safety) GF Score™ of 93/100 indicates high reliability of the DCF inputs What Is SYK Worth? DCF Earnings-Based Model The DCF earnings-based model for Stryker Corp utilizes a two-stage approach to estimate intrinsic value. In the first stage, we project earnings growth over the next ten years, followed by a terminal growth phase. The assumptions used in this model are critical for deriving an accurate valuation.
Parameter Value Current EPS (TTM, excl. non-recurring) $13.39 10-Year Growth Rate 9.4% 10-Year Treasury Rate 4.33% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% In the growth phase (Years 1-10), we expect EPS to grow at 9.4% per year, discounted at a rate of 11%. The calculated value for this stage is $123.73 per share. In the terminal phase (Years 11-20), we assume a slower growth rate of 4%, also discounted at 11%, yielding a terminal stage value of $82.36 per share. The summary of these calculations is presented in the table below:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 9.4%, discounted at 11% $123.73 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $82.36 Intrinsic Value Growth + Terminal $206.09 Comparing the current price of $282.58 with the intrinsic value of $206.09 indicates that Stryker Corp is modestly overvalued, with a margin of safety of -37.1%. It is important to note that GuruFocus uses EPS excluding non-recurring items, as research shows that stock prices correlate more closely with earnings than free cash flow. For further details, visit the SYK DCF Calculator.
What Does the Free Cash Flow DCF Say? The free cash flow (FCF) based intrinsic value for Stryker Corp is calculated at $286.38. When compared to the earnings-based intrinsic value of $206.09, the FCF model suggests a more favorable valuation, indicating that the stock is fair valued with a margin of safety of 1.3%. This difference highlights the importance of considering multiple valuation approaches to gain a comprehensive view of a company's worth.
How Does GF Value™ Compare to the DCF Models? The GF Value™ for Stryker Corp stands at $405.84, providing a third perspective on valuation. GF Value™ is GuruFocus' proprietary measure that incorporates historical trading multiples, past business growth, and future performance estimates. While the DCF earnings-based model suggests overvaluation, the FCF model indicates fair valuation, and GF Value™ suggests that the stock is undervalued. This divergence among the models emphasizes the need for careful consideration when evaluating investment opportunities. For more information, visit the GF Value™ page.
What Does SYK's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been shown to generate higher long-term returns based on backtested data from 2006-2021. Below is a summary of Stryker Corp's GF Score™:
Metric Rating GF Score™ 93/100 Financial Strength 5/10 Profitability 9/10 Growth 10/10 Valuation 8/10 Momentum 5/10 With a predictability rank of 1/5 stars, the reliability of the DCF model for Stryker Corp is lower, indicating that investors should exercise caution when interpreting the results. For more details, visit the SYK stock page.
Key Assumptions and Limitations It is essential to recognize that DCF models are highly sensitive to growth rate and discount rate assumptions. Additionally, stocks with low predictability ratings tend to produce less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not accurately reflect future performance.
What This Means for Investors In summary, the DCF earnings-based model indicates that Stryker Corp is overvalued, while the FCF model suggests it is fairly valued. The GF Value™ further implies that the stock is undervalued. Therefore, the consensus across these three valuation models presents a mixed picture, with a clear verdict leaning towards fair valuation. For the full DCF analysis, visit the SYK DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.
Frequently Asked Questions What is SYK's intrinsic value based on DCF?
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Surgical robotics is quietly becoming an artificial intelligence story. Every robotic procedure generates structured video, kinematic, and outcomes data that platforms feed back into surgeon training, intraoperative guidance, and predictive analytics. That flywheel is the moat. The three companies owning the installed bases to build it are Intuitive Surgical (NASDAQ: ISRG | ISRG Price Prediction), Medtronic (NYSE: MDT), and Stryker (NYSE: SYK). With all three trading well off their 2026 highs, the AI sleeper thesis looks more compelling.
3. Stryker (Mako and the New Ortho Tech Stack) Stryker is the diversified medtech giant with the Mako robotic orthopedic franchise. Q1 FY26 showed adjusted EPS of $2.60, which missed the $2.98 estimate, as well as revenue of $6.02 billion, which came in short of the $6.33 billion consensus. CEO Kevin Lobo cited a March 11, 2026, cybersecurity incident and $118 million in structural optimization charges that compressed adjusted operating margin to 21.1% from 22.9%.
The AI angle lives in the newly carved-out Ortho Tech business, which combines Mako robotic-assisted surgery with power tools, cutting accessories, and enabling technologies. Knees grew 4.7% and hips 3.7%, both Mako-tethered categories. Lobo said, “I am pleased with our team’s ability to recover quickly from the cyber incident…. We remain committed to meeting our full year guidance.” Guidance was maintained at 8.0% to 9.5% organic sales growth and adjusted EPS of $14.90 to $15.10. The risk is that Mako revenue is bundled, so investors cannot isolate the AI orthopedics flywheel. Shares are down 21.3% over the past year.
2. Medtronic (Hugo Goes Live) Medtronic took its biggest step into the robotics race when the Hugo robotic-assisted surgery system received U.S. FDA clearance, with first cases completed in February 2026. Q3 FY26 revenue of $9.017 billion beat the $8.892 billion estimate, and non-GAAP EPS of $1.36 topped the $1.3351 consensus. Cardiac Ablation Solutions stood out, with pulsed field ablation driving revenue up 80% overall and 137% in the United States.
Beyond Hugo, Medtronic cleared the Stealth AXiS Surgical System for spinal procedures and secured a CE Mark for the Sphere-360 mapping catheter, with AI-adjacent mapping and navigation embedded in both. CEO Geoff Martha said, “Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance…. It’s an exciting time for Medtronic.” Non-GAAP gross margin slipped to 64.9% from 66.6%, and a $185 million tariff headwind is baked into FY26 guidance of about 5.5% organic growth and $5.62 to $5.66 EPS. At a forward P/E of 14x and analyst target of $108, the diversified med-device exposure looks attractively priced after a 20.2% year-to-date drawdown.
1. Intuitive Surgical (the Data Flywheel Leader) Intuitive Surgical is the cleanest expression of the thesis. Q1 FY26 non-GAAP EPS of $2.50 beat the $2.11 estimate by 18.66%, the fourth consecutive EPS beat. Revenue of $2.77 billion grew 22.96% year over year, anchored by $1.69 billion in Instruments & Accessories, the high-margin razor-blade line that scales with procedure volume.
The installed base is the moat. Some 11,395 da Vinci systems (up 12%) and 1,041 Ion systems (up 22%) feed procedural data back to Intuitive’s digital platforms for surgeon analytics and training. Of the 431 da Vinci placements in the quarter, 232 were da Vinci 5 units, the AI-ready next-generation platform. Procedures grew 16% for da Vinci and 39% for Ion. Operating income jumped 47.95%, and the company holds $7.98 billion in cash after repurchasing 2.3 million shares for $1.1 billion. CEO Dave Rosa said the quarter “was marked by expanded adoption of our da Vinci, Ion, and digital platforms.” FY26 guidance calls for 13.5% to 15.5% da Vinci procedure growth. However, tariff exposure across Mexico, Germany, and China is embedded as a 1.0% margin headwind. With shares down 24.3% year to date, institutional patience is being tested while insiders accumulate equity grants.
The Verdict Surgical robotics platforms are becoming AI-enabled systems whose data flywheels create durable moats, yet the market treats this thesis as immaterial. Intuitive Surgical is the purest expression, with the largest robotic installed base in healthcare and a digital platform that scales with every procedure. Medtronic is the diversified med-device hedge, now with the Hugo system cleared and the fastest-growing PFA franchise in cardiac care. Stryker is the orthopedic specialist whose Mako story is intact but temporarily clouded by a cyber incident and one-time charges. Together, they offer exposure to AI in operating rooms without software-stock multiples.
Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Stryker (SYK). But which of these two stocks is more attractive to value investors?
POWER CAD I study will evaluate feasibility of the Pulse IVL™ system in patients with severely calcified coronary arterial disease
BOSTON--(BUSINESS WIRE)--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, today announced the enrollment of the first patient in its first-in-human (FIH) study for Pulsatile Intravascular Lithotripsy (PIVL) therapy in a coronary indication.
The POWER CAD I study will evaluate the feasibility of the Pulse IVL™ System for the treatment of patients with moderate to severely calcified coronary arterial disease. Dr. Jithendra Somaratne, interventional cardiologist at Auckland City Hospital and The Heart Group in Auckland, New Zealand, conducted the first case. The study will enroll up to 15 subjects at up to four facilities in Australia and New Zealand, with primary endpoints assessed at 30 days.
“AVS is the only intravascular lithotripsy company to utilize a unique hydraulic mechanism of action, and this is the first step in understanding the patient population that may be able to benefit from our innovative technology,” said Tim Lanier, President, Stryker’s Peripheral Vascular division. “This marks a significant clinical milestone for us as we aim to expand the application of our technology to coronary disease. We are confident our Pulse IVL system, which is designed for easy delivery and efficient treatment of complex calcified lesions, can help elevate care in the IVL space.”
“The team at Auckland City Hospital is proud to enroll the first patient in the POWER CAD I FIH study, and we are grateful to be the first hospital to treat a patient with coronary calcific disease with this innovative approach to Intravascular Lithotripsy,” Dr. Somaratne said. “We found the device to be very deliverable and incredibly efficient at modifying calcium and ultimately enabling maximal stent expansion.”
“A new, innovative treatment for calcified coronary artery disease can make a meaningful impact on patient lives and improve outcomes,” said Associate Professor Robert Gooley, MD, Deputy Director and Head of Interventional Cardiac Services at Monash Health in Melbourne, Australia, and Principal Investigator of the POWER CAD I Study. “Our goal is for the results of this FIH study to pave the way for a new treatment option in an evolving and exciting area of medicine: IVL therapy.”
About AVS
Amplitude Vascular Systems (AVS) is a medical device company based in Boston, MA, focused on treating severely calcified arterial disease. AVS was recently acquired by Stryker, with the deal officially closing on May 7, 2026. To learn more about pulsatile intravascular lithotripsy, visit www.avspulse.com.The Pulse Coronary Intravascular Lithotripsy (IVL) System is an investigational device and not yet cleared for commercial distribution within or outside the United States.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Three companies with strong roots in the state are revolutionizing the treatment of cardiovascular disease through hydraulic lithotripsy technology
CHARLEVOIX, Mich.--(BUSINESS WIRE)--BioStar Capital, a venture capital firm focused on transformative medical technologies, has announced a landmark pre-FDA exit of Amplitude Vascular Systems, Inc. (AVS), a medical technology company that created a next-generation hydraulic intravascular lithotripsy (IVL) platform to treat calcified peripheral arterial disease. Upon acquiring AVS for up to $835 million, Stryker (NYSE:SYK), a global leader in medical technologies, called the deal a milestone in the expansion of its peripheral vascular portfolio.
All three companies have close ties to Michigan. BioStar Capital, with offices in Michigan and Ohio, was founded by Dr. Louis Cannon, a physician who first encountered the idea for hydraulic lithotripsy while serving on the University of Michigan’s Coulter Committee. Robert Chisena, Ph.D, co-founded AVS while completing his doctorate at the university, building prototypes in an Ann Arbor garage. He developed the technology in partnership with Hitinder S. Gurm, an interventional cardiologist and interim Chief Medical Officer of the U of M Health System. Stryker is headquartered in Portage, in southwest Michigan.
About 1 in 20 U.S. adults, aged 20 and older, have calcified arteries, the treatment of which costs approximately $100 billion in aggregate annually. AVS’s Pulse System is a much-needed alternative to the current interventions that use electric wired balloons and lasers. AVS’s technology, which delivers CO₂-generated pressure waves through a balloon catheter, optimizes arterial diameter while potentially minimizing damage and increasing catheter deliverability, treatment speed, and therapeutic efficacy.
BioStar Capital served as an early strategic growth partner of AVS, licensing the IP, providing initial startup capital, and guiding the startup through several phases of development and approvals, including clinical studies and first-in-human trial design.
“We are doctors first and investors second, which means we look for emerging technologies that solve the needs of physicians and patients, then work to make the product better and scalable,” said Cannon, BioStar’s Senior Managing Director. “The data shows that this device is uniquely safe and effective.”
“Its potential for tremendous impact on patients’ lives has only increased with the benefit of Stryker’s resources and reach,” Cannon added.
This acquisition is the latest in a long history of successful exits for BioStar Capital. Among others, the firm previously invested in Corindus Vascular Robotics (NYSE: CVRS), a leader in robotic-assisted vascular interventions that was acquired by Siemens Healthineers for $1.1 billion; V-Wave, a company addressing heart failure that was acquired by Johnson & Johnson for up to $1.7 billion; and CathWorks, developer of an AI-powered imaging platform for coronary artery disease that was acquired by Medtronic in a deal valuing up to $585 million.
About BioStar Capital
BioStar Capital invests in and nurtures transformative medical technologies. The team consists of renowned healthcare clinicians, medical thought leaders, and financial professionals who bring unique insight to every investment opportunity. By leveraging a rare combination of domain expertise, industry connections, and access to medical facilities and innovators, BioStar Capital has consistently produced life-changing outcomes for patients and rewarding returns for investors.
AMSTERDAM--(BUSINESS WIRE)--Stryker (NYSE:SYK), a global leader in medical technologies, announced today the European launch of its Pangea Plating System, a plating platform for the treatment of a wide range of fracture patterns. Prof. Alex Trompeter, design surgeon and orthopaedic trauma surgeon, along with his team at St. George's University Hospital in London, completed the first clinical case in Europe.
“Pangea was developed with a clear goal in mind: supporting anatomical fit while maintaining simplicity in the operating room,” said Prof. Trompeter. “The system brings together thoughtfully designed plates and a streamlined instrumentation set, giving surgeons practical options when treating a range of fractures.”
The devices are non-active implants intended to provide temporary stabilization for bones or bone fragments. The system includes plates and complementary instrumentation intended to support plate fit and provide surgeons with options for fracture fixation across the upper and lower extremities.
“Having used the system in the U.S., I’ve seen how it supports consistent workflows while offering flexibility in fracture fixation,” said Arvind von Keudell, MD, PhD, MPH, fellowship-trained, board-certified orthopaedic surgeon and associate professor at Harvard Medical School. “It’s designed in a way that helps surgeons adapt to different fracture patterns without adding unnecessary complexity in the operating room.”
Developed in collaboration with 26 orthopaedic surgeons from around the world, the Pangea portfolio incorporates global anatomical data to support plate fit across diverse patient populations. The platform also provides variable-angle plating designed to offer flexibility in screw placement.
“We are pleased to introduce the Pangea Plating System to surgeons across Europe,” said Dragana Bunjevac, vice president and general manager of Stryker’s Trauma & Extremities division in EMEA. “Pangea reflects our focus on developing solutions that enhance surgical workflow and address the evolving needs of trauma care.”
The European launch expands access to Stryker’s trauma portfolio and reflects the company’s continued collaboration with orthopaedic surgeons worldwide to develop solutions that support fracture fixation.
For more information about the Pangea Plating System, please visit our website.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
This document is intended solely for the use of healthcare professionals. A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.
The information presented is intended to demonstrate a Stryker product. A surgeon must always refer to the package insert, product label and/or instructions for use, including the instructions for cleaning and sterilization (if applicable), before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.
The instructions for use, operative techniques, cleaning instructions, patient information leaflets and other associated labeling may be requested online at ifu.stryker.com or stryker.com. If saving the instructions for use, operative techniques, cleaning instructions from the above mentioned websites, please make sure you always have the most up to date version prior to use.
Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Pangea, Stryker. All other trademarks are trademarks of their respective owners or holders.
Stryker NYSE:SYK , a global leader in medical technologies, announced today the European launch of its Pangea Plating System, a plating platform for the treatment of a wide range of fracture patterns. Prof. Alex Trompeter, design surgeon and orthopaedic trauma surgeon, along with his team at St. George's University Hospital in London, completed the first clinical case in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525326817/en/
Stryker's Pangea Plating System brings together thoughtfully designed plates and a streamlined instrumentation set, giving surgeons practical options when treating a range of fractures.
“Pangea was developed with a clear goal in mind: supporting anatomical fit while maintaining simplicity in the operating room,” said Prof. Trompeter. “The system brings together thoughtfully designed plates and a streamlined instrumentation set, giving surgeons practical options when treating a range of fractures.”
The devices are non-active implants intended to provide temporary stabilization for bones or bone fragments. The system includes plates and complementary instrumentation intended to support plate fit and provide surgeons with options for fracture fixation across the upper and lower extremities.
“Having used the system in the U.S., I’ve seen how it supports consistent workflows while offering flexibility in fracture fixation,” said Arvind von Keudell, MD, PhD, MPH, fellowship-trained, board-certified orthopaedic surgeon and associate professor at Harvard Medical School. “It’s designed in a way that helps surgeons adapt to different fracture patterns without adding unnecessary complexity in the operating room.”
Developed in collaboration with 26 orthopaedic surgeons from around the world, the Pangea portfolio incorporates global anatomical data to support plate fit across diverse patient populations. The platform also provides variable-angle plating designed to offer flexibility in screw placement.
“We are pleased to introduce the Pangea Plating System to surgeons across Europe,” said Dragana Bunjevac, vice president and general manager of Stryker’s Trauma & Extremities division in EMEA. “Pangea reflects our focus on developing solutions that enhance surgical workflow and address the evolving needs of trauma care.”
The European launch expands access to Stryker’s trauma portfolio and reflects the company’s continued collaboration with orthopaedic surgeons worldwide to develop solutions that support fracture fixation.
For more information about the Pangea Plating System, please visit our website.
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
This document is intended solely for the use of healthcare professionals. A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.
The information presented is intended to demonstrate a Stryker product. A surgeon must always refer to the package insert, product label and/or instructions for use, including the instructions for cleaning and sterilization (if applicable), before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.
The instructions for use, operative techniques, cleaning instructions, patient information leaflets and other associated labeling may be requested online at ifu.stryker.com or stryker.com. If saving the instructions for use, operative techniques, cleaning instructions from the above mentioned websites, please make sure you always have the most up to date version prior to use.
Stryker Corporation or its divisions or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Pangea, Stryker. All other trademarks are trademarks of their respective owners or holders.
Content ID: TR-PANG-PRESS-3206883
View source version on businesswire.com: https://www.businesswire.com/news/home/20260525326817/en/
Key Takeaways SYK launched the Pangea Plating System in Europe and completed the first clinical case in London.Pangea includes non-active implants, plates and instruments to stabilize upper and lower limb fractures.Co-developed with 26 surgeons, Pangea uses global anatomical data and variable-angle plating flexibility. Stryker (SYK - Free Report) recently announced the European launch of its Pangea Plating System, a plating platform developed for the treatment of a broad range of fracture patterns. The company also completed the first clinical case in Europe at St. George’s University Hospital in London, led by design surgeon and orthopedic trauma surgeon Prof. Alex Trompeter and his team.
Per management, the company is excited to bring the Pangea Plating System to surgeons across Europe. The Pangea Plating System highlights Stryker’s commitment to creating solutions that improve surgical efficiency and meet the changing demands of trauma care.
Likely Trend of SYK Stock Following the NewsFollowing the announcement, SYK shares lost 1.1% at yesterday’s closing. In the year-to-date period, shares of the company have declined 10.9% compared with the industry’s 22.1% fall. However, the S&P 500 has risen 9.6% in the same timeframe.
Stryker is likely to benefit from the European launch of its Pangea Plating System, as the expansion strengthens its trauma and extremities portfolio in a key international market. The launch could drive higher adoption among orthopedic surgeons, backed by the system’s flexibility, simplified workflow and broad fracture fixation capabilities. Collaboration with global surgeons and successful early clinical use may also enhance Stryker’s reputation for innovation in trauma care.
SYK currently has a market capitalization of $121.33 billion.
Image Source: Zacks Investment Research
More on the Pangea Plating SystemThe Pangea Plating System includes non-active implants designed to temporarily stabilize fractured bones and bone fragments. The system features specialized plates and supporting instruments aimed at improving anatomical fit while giving surgeons multiple fixation options for both upper and lower limb fractures.
Created in partnership with 26 orthopedic surgeons globally, the Pangea portfolio leverages international anatomical data to enhance compatibility across a broad range of patients. It also includes variable-angle plating, allowing greater flexibility in screw positioning.
The European rollout broadens access to Stryker’s trauma solutions portfolio and highlights the company’s collaboration with orthopedic specialists to advance fracture fixation treatments.
Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the trauma and extremities devices market is valued at $16.55 billion in 2026 and is expected to witness a CAGR of 5.2% through 2034.
The market is expanding, driven by advances in minimally invasive surgical techniques, such as intramedullary nails and locking plate systems, which promote faster healing and reduce soft tissue trauma. The rising number of orthopedic disorders and injuries, along with the increased adoption of automation, is also driving market growth.
Other NewsStryker recently completed the acquisition of Amplitude Vascular Systems, the developer of a next-generation intravascular lithotripsy platform for the treatment of calcified peripheral arterial disease.
This acquisition is aimed at enhancing Stryker’s Peripheral Vascular (PV) portfolio by introducing innovative revascularization capabilities. Following regulatory clearance in relevant markets, the technology is anticipated to complement the company’s existing PV solutions and its strategy to grow in the arterial disease treatment space.
SYK’s Zacks Rank & Key PicksStryker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
On June 02, 2026, we present a DCF analysis for Stryker Corp SYK amidst its recent price performance, which has seen a decline of 14.6% year-to-date and 21.0% over the past year. The current price stands at $299.46.
DCF Earnings-based intrinsic value of $206.09 vs price of $299.46 (margin of safety: -45.3%) DCF FCF-based intrinsic value of $286.38 vs price of $299.46 (second opinion) GF Score™ of 92/100 indicates a high reliability of the DCF inputs What Is SYK Worth? DCF Earnings-Based Model The DCF earnings-based model for Stryker Corp employs a two-stage approach. In the first stage, we project earnings growth over the next 10 years at a rate of 9.4%. This growth is then discounted back to present value using a discount rate of 11%, which is derived from the risk-free rate and equity risk premium. In the second stage, we apply a terminal growth rate of 4% for the subsequent 10 years, also discounted at the same rate.
Parameter Value Current EPS (TTM, excl. non-recurring) $13.39 10-Year Growth Rate 9.4% 10-Year Treasury Rate 4.43% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% The calculation summary for the DCF earnings-based model is as follows:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 9.4%, discounted at 11% $123.73 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $82.36 Intrinsic Value Growth + Terminal $206.09 Comparing the current price of $299.46 with the intrinsic value of $206.09 reveals that Stryker Corp is modestly overvalued, with a margin of safety of -45.3%. It is important to note that GuruFocus uses EPS excluding non-recurring items, as research indicates that stock prices correlate more closely with earnings than with free cash flow. For further calculations, visit the SYK DCF Calculator.
What Does the Free Cash Flow DCF Say? The free cash flow (FCF) based intrinsic value for Stryker Corp is calculated at $286.38. When compared with the earnings-based intrinsic value of $206.09, the FCF model suggests a somewhat higher valuation. This indicates that while the earnings-based model shows Stryker as overvalued, the FCF-based model presents it as fairly valued, with a margin of safety of -4.6%.
How Does GF Value™ Compare to the DCF Models? The GF Value™ for Stryker Corp is calculated at $408.28, providing a third perspective on valuation. GF Value™ is GuruFocus' proprietary measure that considers historical trading multiples, past business growth, and future performance estimates. In this case, the DCF earnings-based model suggests overvaluation, the FCF model indicates fair valuation, while GF Value™ suggests that the stock is undervalued. This discrepancy highlights the importance of considering multiple valuation methods. For more details, visit the GF Value™ page.
What Does SYK's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns based on backtested data from 2006 to 2021.
Metric Rating GF Score™ 92/100 Financial Strength 7/10 Profitability 9/10 Growth 10/10 Valuation 8/10 Momentum 4/10 With a predictability rank of 1/5 stars, it indicates that the DCF model may be less reliable for this stock. For more information, visit the SYK stock page.
Key Assumptions and Limitations It is essential to recognize that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Stocks with low predictability ratings, such as Stryker Corp, tend to produce less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not accurately reflect future economic conditions.
What This Means for Investors In synthesizing the three valuation models—DCF earnings, DCF FCF, and GF Value™—we find a mixed picture. The DCF earnings model indicates that Stryker Corp is overvalued, while the DCF FCF model suggests fair valuation. Conversely, the GF Value™ indicates it is undervalued. Overall, the consensus leans towards overvaluation based on earnings.
For the full DCF analysis, visit the SYK DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.
Frequently Asked Questions What is SYK's intrinsic value based on DCF?
earnings-based $206.09, FCF-based $286.38
Is SYK overvalued or undervalued?
Based on the DCF earnings model, SYK is overvalued, while the FCF model suggests it is fairly valued, and GF Value™ indicates it is undervalued.
How reliable is the DCF model for SYK?
The predictability rank of 1/5 suggests that the DCF model may be less reliable for Stryker Corp.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
, /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced the launch of its TPX HD, a premium small bone power tool designed to support performance, control and ergonomics in a wide range of challenging orthopaedic procedures such as total joint revisions, minimally invasive surgery and oral maxillofacial procedures.
Stryker's TPX HD® power tool
Stryker's TPX HD® power tool "Revision procedures are some of the most demanding cases surgeons face, especially when metal cutting is involved," said Mike Carlin, president of Stryker's Ortho Tech division. "TPX HD was designed with those moments in mind, when visibility is limited, precision matters and surgeons need a tool they can trust to perform."
TPX HD incorporates several design features aimed at improving performance and usability, including a tapered attachment design for improved visibility in confined spaces, a housing designed to act as a barrier for motor heat at high speeds and enhanced ergonomics through a shorter handpiece length and improved grip.*
Key system features include:
Power and speed, delivering up to 296% more torque** and 40% faster performance* compared to the TPX Micro Drill at high speed Customizable control, enabled via I.D. Touch software within Stryker's CORE™ 2 Console, allowing surgeons to tailor drill response and sensitivity Specialized attachments, including multiple attachment lengths, a PROStep™ 5:1 reducer and capability for metal and bone cement cutting and removal For more information, visit https://www.stryker.com/us/en/orthopaedic-instruments/products/tpx-hd.html
*As compared to TPX Micro Drill
**As compared to TPX Micro Drill at high speed
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC - Free Report) or Stryker (SYK - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Phibro Animal Health has a Zacks Rank of #2 (Buy), while Stryker has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that PAHC likely has seen a stronger improvement to its earnings outlook than SYK has recently. But this is just one factor that value investors are interested in.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
PAHC currently has a forward P/E ratio of 9.28, while SYK has a forward P/E of 19.58. We also note that PAHC has a PEG ratio of 0.43. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. SYK currently has a PEG ratio of 1.85.
Another notable valuation metric for PAHC is its P/B ratio of 3.2. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, SYK has a P/B of 4.89.
Based on these metrics and many more, PAHC holds a Value grade of A, while SYK has a Value grade of C.
PAHC sticks out from SYK in both our Zacks Rank and Style Scores models, so value investors will likely feel that PAHC is the better option right now.
Key Takeaways Stryker launched TPX HD, a small bone power tool for total joint revisions, MIS and oral maxillofacial use.SYK shares rose 0.6% after Tuesday's launch; the stock is down 16.1% YTD vs. the industry's 26.3% fall.TPX HD boosts visibility and precision in metal cutting, with custom drill settings via CORE 2 Console. Stryker (SYK - Free Report) recently announced the launch of TPX HD, an advanced small bone power tool engineered to support performance, control and ergonomics across a range of complex orthopedic procedures. The tool is intended for use in total joint revisions, minimally invasive surgery and oral maxillofacial procedures.
Per management, revision surgeries are among the most complex procedures surgeons face, particularly those involving metal cutting. TPX HD was specifically developed to address these challenges by providing enhanced visibility, precision and reliable performance.
Likely Trend of SYK Stock Following the NewsShares of SYK have gained 0.6% since the announcement on Tuesday. In the year-to-date (YTD) period, shares of the company have lost 16.1% compared with the industry’s 26.3% decline. However, the S&P 500 has risen 11% in the same timeframe.
Stryker is likely to gain from the launch of TPX HD as it expands the company’s portfolio of advanced surgical power tools tailored for complex orthopedic procedures. By improving surgical efficiency and integrating seamlessly with existing tools, TPX HD could support broader adoption among healthcare providers. The launch also underscores Stryker’s continued innovation to strengthen its position in the orthopedics market and support future growth.
SYK currently has a market capitalization of $112.44 billion.
Image Source: Zacks Investment Research
More on the TPX HD Power ToolThe TPX HD features a tapered attachment design that improves visibility in confined surgical spaces, a heat-resistant housing that minimizes motor heat during high-speed use and a shorter handpiece with an improved grip.
The power tool delivers up to 296% higher torque and operates 40% faster than the TPX Micro Drill at high speeds. It offers customizable control through Stryker’s I.D. Touch software within the CORE 2 Console, allowing surgeons to tailor drill response and sensitivity.
The system also offers specialized attachments, including various attachment lengths, a PROStep 5:1 reducer and tools designed for cutting and removing metal and bone cement. The system remains compatible with existing foot pedals, the TPX HD hand switch, the CORE 2 Console and a broad range of cutting accessories, supporting seamless integration.
Industry Prospects Favoring the MarketGoing by the data provided by Precedence Research, the orthopedic devices market is valued at $68.64 billion in 2026 and is expected to witness a CAGR of 4.3% through 2035.
The market is expanding, driven by the rising prevalence of orthopedic disorders, an aging population and injury incidence, advancements in orthopedic technologies and greater healthcare access and reimbursement support.
Other NewsStryker recently completed the acquisition of Amplitude Vascular Systems, the developer of a next-generation intravascular lithotripsy platform for the treatment of calcified peripheral arterial disease.
This acquisition is aimed at enhancing Stryker’s Peripheral Vascular (PV) portfolio by introducing innovative revascularization capabilities. Following regulatory clearance in relevant markets, the technology is anticipated to complement the company’s existing PV solutions and its strategy to grow in the arterial disease treatment space.
SYK’s Zacks Rank & Key PicksStryker currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Key Takeaways Stryker maintained healthy underlying demand despite cyberattack-related shipment disruptions.SYK reported record Mako installations as adoption and utilization rates increased globally.Stryker sees growth from international expansion and Amplitude Vascular Systems acquisition. Stryker (SYK - Free Report) entered 2026 facing an unexpected cyber disruption, yet underlying demand, robotics adoption and international momentum remained strong. While a robust capital pipeline and active acquisition strategy support long-term growth, execution risks tied to recovery efforts, margin pressures and expanding exposure to new markets could shape the company’s performance over the coming quarters.
This Zacks Rank #3 (Hold) company’s shares have lost 13.1% so far this year compared with the industry’s 23.1% decline. The S&P 500 Index has gained 6.3% in the same time frame.
Stryker is a global leader in medical technology with a portfolio spanning Orthopaedics, MedSurg, and Neurotechnology. The company has a market capitalization of $118.4 billion.
SYK’s bottom line is anticipated to improve 10.6% over the next five years. Its earnings beat estimates in each of the trailing four quarters, delivering an average negative surprise of 1.82%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Factors Driving SYK’s ProspectsStrong Underlying Procedure Demand and Robust Capital Order Book: Despite the cyberattack significantly disrupting first-quarter results, management repeatedly emphasized that underlying demand across its major businesses remained healthy. Organic sales growth of 2.4% was heavily constrained by shipment delays and revenue-recognition disruptions rather than weakening customer demand.
Hospital capital spending remains stable, and Stryker entered the second half of 2026 with an elevated capital equipment order book, providing solid visibility into future demand. The company also delivered a record first quarter for Mako installations across both domestic and international markets, while Mako utilization rates continued to increase.
These indicators suggest that end-market fundamentals remain intact. Once operational disruptions normalize, the combination of strong procedural volumes, demographic tailwinds and sustained hospital investment should allow Stryker to resume its historical pattern of above-market growth and reinforce its leadership position across orthopaedics and medical technologies.
Robotics Ecosystem Continues to Create a Powerful Competitive Moat: Stryker’s robotics platform remains one of its most important strategic advantages. Management highlighted record Mako installations, strong surgeon adoption and increasing utilization rates globally. The company is expanding the platform through Mako 4, Mako Shoulder and the newly launched Mako RPS handheld robotic solution. The handheld robotic solution broadens access to surgeons previously reluctant to adopt full robotic systems.
Advanced hip revision procedures are receiving strong clinical feedback, while future procedural expansions remain under development. The ability to continuously add applications onto an installed robotic base strengthens customer retention and drives recurring implant demand.
Management continues to expect orthopaedic growth to exceed market rates by 200-300 basis points. As robotic adoption expands across hospitals and ambulatory surgery centers, Stryker’s ecosystem advantage could become even more difficult for competitors to replicate.
International Markets Are Emerging as a Major Growth Engine: International operations are becoming increasingly important to Stryker’s growth profile. Management cited strong momentum in Japan, Europe, India, Korea and broader East Asia, supported by years of commercial investment and expanding product approvals.
Europe recently approved Pangea, a platform that has already driven significant trauma growth in the United States and Japan. The company also sees significant long-term opportunities in Saudi Arabia and other Middle Eastern markets despite current geopolitical challenges.
Management believes market share remains below its potential across several international regions, leaving ample room for future expansion. As more U.S.-developed innovations receive international approvals, Stryker gains additional leverage from its global infrastructure. This growing geographic diversification reduces dependence on any single market and provides a meaningful runway for sustained revenue acceleration over the coming years.
DownsidesCyberattack Exposes Significant Operational Vulnerabilities: The most immediate risk facing Stryker is the operational disruption caused by the recent cyberattack. Although management successfully restored manufacturing systems and reaffirmed full-year guidance, the incident highlighted the company’s dependence on interconnected digital infrastructure.
The attack disrupted manufacturing, delayed shipments and reduced revenue recognition, hurting first-quarter profitability. While management characterized the recovery as successful, future cybersecurity threats remain a material risk, given the increasingly digital nature of healthcare operations.
Beyond direct financial costs, the company expects to incur additional investments related to cybersecurity enhancements and operational resilience. Even though customer relationships appear largely intact, the event demonstrates how quickly external disruptions can materially affect financial performance, particularly across a global organization with complex manufacturing and distribution networks.
Margin Expansion Faces Pressure: Stryker’s profitability outlook remains challenged by several external factors. First-quarter adjusted gross margin declined 190 basis points, while operating margin fell 180 basis points due to lost manufacturing absorption, tariffs and lower operating leverage.
Interest expense increased following a debt issuance used to fund the Inari acquisition. Management acknowledged ongoing inflationary pressure from rising input costs, freight expenses and geopolitical developments affecting commodity markets. While procurement initiatives and operational-efficiency programs may mitigate part of these pressures, much of the inflationary environment remains outside management’s control.
The company continues to target margin expansion, but achieving those objectives may become increasingly difficult if tariff uncertainty persists or global inflation remains elevated. Sustained cost pressure could limit earnings growth even if revenue recovery proceeds according to plan.
Growing Exposure to Emerging Businesses Increases Risk: Stryker’s expansion into newer categories, such as peripheral vascular intervention, cardiovascular technologies, AI-enabled hospital solutions and potentially soft-tissue robotics, offers significant growth opportunities but brings in execution complexity.
Businesses like Inari and the planned AVS acquisition require the company to operate in physician specialties and competitive environments outside its traditional orthopaedic expertise. Management has acknowledged that successful integration requires commercial restructuring, retention of talent and continued investment in innovation.
Newer technologies often involve regulatory uncertainty, reimbursement challenges and longer adoption cycles. While these initiatives have the potential to create substantial long-term value, they also add operational complexity and increase the risk that capital investments may not deliver the anticipated returns. Investors must weigh the growth opportunity against the execution risks associated with entering new markets.
Estimate TrendSYK has been witnessing a positive estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for earnings has increased 0.5% to $14.98 per share.
The consensus mark for second-quarter 2026 revenues is pegged at $6.56 billion, indicating a 9% improvement from the year-ago reported actuals. The bottom-line estimate is pinned at $3.49, implying year-over-year growth of 11.5%.
Stocks to ConsiderSome better-ranked stocks from the same medical industry are Align Technology (ALGN - Free Report) , West Pharmaceutical Services (WST - Free Report) and Cardinal Health (CAH - Free Report) .
Align Technology, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 10.3%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 7.80%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ALGN’s shares have gained 9.2% against the industry’s 4.2% decline so far this year.
West Pharmaceutical, currently carrying a Zacks Rank of 1, has an estimated long-term growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 19.37%.
West Pharmaceutical’s shares have gained 20.2% against the industry’s 4.2% decline year to date.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.
CAH’s shares have gained 5.2% against the industry’s 4.2% decline so far this year.
